Deakin University
Browse
- No file added yet -

Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia

Download (61.29 kB)
Version 2 2024-06-13, 11:32
Version 1 2018-09-12, 11:51
journal contribution
posted on 2024-06-13, 11:32 authored by D Liew, N Patten, M Tan, H Kim
Cost utility analysis (CUA) of nivolumab compared to everolimus for the treatment of metastatic renal cell carcinoma (RCC) in Australia

History

Journal

Value in health

Volume

20

Season

October-November

Pagination

A444-A444

Location

Amsterdam, The Netherlands

Publisher DOI

Open access

  • Yes

Link to full text

ISSN

1098-3015

Language

eng

Publication classification

C2 Other contribution to refereed journal

Copyright notice

2017, Elsevier

Issue

9

Publisher

Elsevier

Usage metrics

    Research Publications

    Categories

    Keywords

    3801 Applied economics

    Licence

    All Rights Reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC